Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology
Main Authors: Buqué, Aitziber, Bloy, Norma, Aranda, Fernando, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Marabelle, Aurélien, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2015
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485728/
https://ncbi.nlm.nih.gov/pubmed/26137403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1008814
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items